Adar Poonawalla, the chief executive officer (CEO) of Serum Institute of India (SII), hailed WHO’s decision as “yet another milestone” in the fight against Covid-19.
Earlier this week, Poonawalla had said that SII planned to launch Covovax in the next six months. He had stated that Covovax, which is under trial, would offer protection to children down to three years as it had shown excellent data during the trials.
“WHO issued an emergency use listing for Covovax, expanding the basket of WHO-validated vaccines against Covid-19,” the world health body said in a tweet on Friday.
According to WHO, Covovax was assessed under its emergency use listing procedure based on the review of data on quality, safety and efficacy, a risk management plan, programmatic suitability, and manufacturing site inspections carried out by Drugs Controller General of India (DCGI).
“The Technical Advisory Group for Emergency Use Listing, convened by WHO and made up of experts from around the world, has determined that the vaccine meets WHO standards for protection against Covid-19, that the benefit of the vaccine far outweighs any risks, and that the vaccine can be used globally,” the tweet said.
Reacting to the development, Poonawalla tweeted, “This is yet another milestone in our fight against Covid-19, Covovax is now WHO approved for emergency use, showing excellent safety and efficacy. Thank you all for a great collaboration…”
Credit: Source link